Awaiting product image

Article: KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer

€2.42

SKU: product-article-8218 Category:

Description

KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer

Reviews

There are no reviews yet.

Be the first to review “Article: KEYNOTE-048 supports pembrolizumab alone or in combination with chemotherapy as standard first-line therapies for recurrent/metastatic head and neck cancer”

Your email address will not be published. Required fields are marked *

Related products